CAS: 1256349-48-0; N-(2-Aminophenyl)-6-((7-Methoxyquinolin-4-yl)Oxy)-1-Naphthamide
- 英文名称N-(2-Aminophenyl)-6-((7-Methoxyquinolin-4-yl)Oxy)-1-Naphthamide
- 中文名称N-(2-氨基苯基)-6-[(7-甲氧基-4-喹啉基)氧基]-1-萘甲酰胺
- IUPAC名称N-(2-aminophenyl)-6-((7-methoxyquinolin-4-yl)oxy)-1-naphthamide
- 其它别名N-(2-Aminophenyl)-6-(7-Methoxyquinolin-4-yl)Oxynaphthalene-1-Carboxamide; Ibcasertib; 1-Naphthalenecarboxamide, N-(2-Aminophenyl)-6-[(7-Methoxy-4-Quinolinyl)Oxy]-; Chiauranib [who-Dd]; N-(
- CAS编号1256349-48-0
- MFCD编号:MFCD34179475
- FDA UNII编号:F40IRN5981
- 分子式:C27H21N3O3分子量:435.48
- 产品CID: 381166
- 产品分类Protein Tyrosine Kinase/RTK → VEGFR | Protein Tyrosine Kinase/RTK → c-FMS | Protein Tyrosine Kinase/RTK → PDGFR | Inhibitors/Agonists → Cell Cycle → Aurora Kinase | Aromatic Heterocycles | Aryls | Protein Tyrosine Kinase/RTK → c-Kit
物理性质
- 沸点604.6±50.0 °C(预测)
- 密度1.333±0.06 g/cm3(预测)
- pKa:12.77±0.70(预测)
- LogP:5.1
- 溶解性DMSO: 62.5 mg/mL (143.52 Mm; Need Ultrasonic)
- 外观形态白色至浅棕色固体
- 储存条件4°C, 避光
- 产品应用该化合物是一种口服活性,多目标抑制器,针对肿瘤血管的产生;它表现出强大的抗癌活动,有效抑制与血管生长有关的动脉(VEGFR1/FLT-1,VEGBFR2/KDR/FLK-1, VEG FR3/FLT-4,PDGFFRΑ和C-KIT),与肾上腺素有关的活性酶AURORA B和炎性相关动脉酶CSF-1R,IC50值介于1至9纳米之间.
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2902902000-精萘
2905110000-甲醇
2912110000-甲醛
2912210000-苯甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Deng M, Shi Y, Chen K, Zhao H, Wang Y, Xie S, Zhao J, Luo Y, Fang Z, Fan Y, Xu B. CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo. Exp Cell Res. 2018 Aug 15;369(2):356-362. doi: 10.1016/j.yexcr.2018.05.038. Epub 2018 Jun 1. doi: 10.1111/cas.13141. Epub 2017 Mar 7.
合成参考文献
参考文献:10.1016/j.ejmech.2022.114884
摘要:Wen J, Wang S, Guo R, Liu D. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. European Journal of Medicinal Chemistry. 2023 Jan;245():114884. doi: 10.1016/j.ejmech.2022.114884.
参考文献:10.1038/s41419-023-05833-w
摘要:Gao T, Huang J, Yin H, Huang J, Xie J, Zhou T, Fan W, Yang X, Gao G, Li Z. Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase. Cell Death Dis. 2023 May 09;14(5):316.
📝 需求与反馈
尽可能描述清楚需求与问题信息
